INDIANAPOLIS and CAMBRIDGE, Mass., July 2 /PRNewswire-FirstCall/ -- Eli Lilly and Company (NYSE: LLY) and Alnara Pharmaceuticals, Inc.

Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced today that the Trizytek( TM) (liprotamase) Phase 3 efficacy study results will be presented at oral and poster sessions at the 2008 North American Cystic Fibrosis Conference (NACFC) in Orlando, FL on October 23 and 24.

Altus Pharmaceuticals Inc. (NASDAQ: ALTU) announced today that its Phase 3 efficacy trial of Trizytek(TM) (porcine-free enzymes) in patients with cystic fibrosis (CF) successfully met its primary endpoint of improvement in fat absorption.

By Kleven, Daniel T McCudden, Christopher R; Willis, Monte S Cystic fibrosis (CF) is the most common lethal genetic disease in Caucasians, occurring in 1/2,500 births.12 In its most common form, CF manifests as progressive lung dysfunction, pancreatic insufficiency, and intestinal disease (see Figure 1).

By Knott, Laurence THE BASICS Proactive management can improve patient survival. By Dr Laurence Knott Cystic fibrosis (CF) affects one in 2,500 newborns and has a UK prevalence of 8,000.